Form 4: Day One Biopharmaceuticals Acquired by Servier

Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, reports the disposal of all equity holdings following the company's acquisition by Servier Pharmaceuticals.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) has been acquired by Servier Pharmaceuticals LLC.
• The merger was finalized on April 23, 2026.
• All outstanding shares of common stock were converted into the right to receive $21.50 per share in cash.
• All unvested stock options and restricted stock units (RSUs) held by the reporting person were fully vested immediately prior to the merger.
• All equity holdings, including options and RSUs, were canceled and converted into cash payments based on the merger consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a standard regulatory disclosure confirming the completion of a previously announced merger.

Positives

• Shareholders received a cash payout of $21.50 per share.
• Accelerated vesting of all outstanding equity awards for the reporting person upon the merger closing.

Negatives

• The company is no longer a publicly traded entity as it has become a wholly owned subsidiary of Servier.

Risks

• None, as the company has been acquired and the reporting person no longer holds equity in the issuer.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; therefore, no further public guidance or forward-looking statements are provided by the issuer.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation trend in the biopharmaceutical sector, where larger established players like Servier are acquiring specialized firms to bolster their oncology or rare disease pipelines.

Comparison to Industry Standards

• The acquisition price reflects a standard premium for biotech M&A activity in the current market environment.
• The structure of the deal (all-cash) is consistent with recent private equity and strategic acquisitions of mid-cap biopharma companies.

Stakeholder Impact

• Shareholders have been cashed out at the agreed merger price.
• Employees and management transition to being part of the Servier organization.

Next Steps

• Delisting of Day One Biopharmaceuticals (DAWN) from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Acquisition, Servier Pharmaceuticals, Form 4, Insider Transaction